The ability of PBM to increase levels of Hsps reveals a functionality that may facilitate the refolding of misfolded aggregates of Aβ and tau that contribute to AD pathology and/or the targeted degradation of these aggregates via the ubiquitin–proteosome system. This evidence concerns the gene MAPT and Alzheimer disease.